Abstract
Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual data from 13 clinical studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to four metabolic phenotypes (poor, intermediate, normal, and ultrarapid) of CYP2C19 and CYP2D6. The association of CYP2C19 and CYP2D6 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033) but did not survive after multiple testing correction. No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19 and CYP2D6, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European and East Asian studies. In conclusion, metabolic phenotypes imputed from genetic variants were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. Information including side effects, antidepressant dosage, as well as population from different ancestries could be involved to fully capture the influence of metabolic phenotypes and improve the power of effect assessment.
Competing Interest Statement
CML has served on the scientific advisory board for Myriad Neuroscience, and is a consultant for UCB. KJA has received two research grants in the last 2 years from Janssen Inc., Canada (fellowship grants for trainees), and provided consultancy services in the last three years for Otsuka Canada Pharmaceutical Inc., Lundbeck Canada, and HLS Therapeutics. AS is or has been consultant/speaker for: Abbott, AbbVie, Angelini, AstraZeneca, Clinical Data, Boehringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, InnovaPharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, and Servier. AMM has received research support from the Sackler Trust and speakers fees from Janssen and Illumina. MK has received grant funding from the Japanese Ministry of Health, Labor and Welfare, the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation, the Japan Research Foundation for Clinical Pharmacology and the Japanese Society of Clinical Neuropsychopharmacology and speakers honoraria from Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Lundbeck Viatris Inc, Eisai Co., Ltd. and Ono Pharmaceutical and participated in an advisory/review board for Otsuka, Sumitomo Pharma, Shionogi and Boehringer Ingelheim. DS has received grant/research support from GlaxoSmithKline and Lundbeck; and served as a consultant or on advisory boards for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, and Lundbeck. CF was a speaker for Janssen. NP is or has been consultant/speaker for: Takeda, Janssen and Lundbeck All other authors report no biomedical financial interests or potential conflicts of interest.
Funding Statement
This study was supported by the NIMH (MH124873) and by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. Chiara Fabbri and Alessandro Serretti were partly supported by #NEXTGENERATIONEU (NGEU), funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006) A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The STAR*D study was approved by institutional ethics review boards at all centres. Written consent was obtained from all participants after the procedures and any associated risks were explained. STAR*D genotype and phenotype data are available through the National Institute of Mental Health Human Genetic Initiative. The GSRD study were approved by the local ethics committees of each participating centre (coordinating centre approval number: B406201213479). The GENDEP study was approved by ethics boards in all participating centres. All participants provided a written consent after the procedures were explained. GENDEP is registered at EudraCT (No.2004-001723-38, http://eudract.emea.europa.eu) and ISRCTN (No. 03693000, http://www.controlledtrials.com). The DAST study was approved by the ethics committee of the University of Muenster, Muenster, Germany, and written informed consent from all subjects were obtained before commencement of any study procedures. The GENPOD study was approved by the South West Ethics Committee (MREC 02/6/076) as well as research governance approval from Bristol, Manchester and Newcastle Primary Care NHS Trusts. The ISRCTN is 31345163 and EudraCT number 2004-001434-16. The GODS study protocol was approved by the ethics committee of the Geneva University Department of Psychiatry and written informed consent was obtained from all subjects. The Japan study was approved by the ethical committee of the Kansai Medical University and Osaka University. Written informed consent was obtained from each subject after a detailed explanation of the study. Written informed consent was obtained from all subjects involved in all studies.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
